Benny, you're being a bit naughty again.
You keep saying that NYR-BIO3 operates downstream of glutamate receptors. That's not really true, is it.
You mean it's downstream of metabotropic glutamate receptors.
But targeting ionotropic glutamate receptors is showing much more promise. Here's a recent review article highlighting at least 30 different novel compounds that show more promise than NYR-BIO3, with a broader action, most of them with ACTUAL proven safety in humans.
https://onlinelibrary.wiley.com/doi/full/10.1002/nep3.46
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.015(6.38%) |
Mkt cap ! $52.72M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 25.0¢ | 23.5¢ | $133.6K | 560.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 31961 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 26751 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |